Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial.
(2011) Blood — Vol. 117, n° 11, p. 3041-3044 (2011)
Files
MoreauPetalBlood2010.pdf
Restricted Access - Adobe PDF
- 420.17 KB
Details
- Authors
- Abstract
- In the 2005-01 trial, we have demonstrated that bortezomib-dexamethasone as induction therapy before autologous stem cell transplantation was superior to vincristine-adriamycin-dexamethasone. We conducted a post-hoc analysis to assess the prognostic impact of initial characteristics as well as response to therapy in patients enrolled in this study. Multivariate analysis showed that ISS stages 2 and 3 and achievement of response less than very good partial response (VGPR) both after induction therapy and after autologous stem cell transplantation were adverse prognostic factors for progression-free survival, the most important one being achievement of response less than VGPR after induction. Progression-free survival was significantly improved with bortezomib-dexamethasone induction therapy in patients with poor-risk cytogenetics and ISS stages 2 and 3 compared with vincristine-adriamycin-dexamethasone. In these 2 groups of patients, achievement of at least VGPR after induction was of major importance. This study is registered with EudraCT (https://eudract.ema.europa.eu; EUDRACT 2005-000537-38) and http://clinicaltrials.gov (NCT00200681).
- Affiliations
Citations
Moreau, P., Attal, M., Pégourié, B., Planche, L., Hulin, C., Facon, T., Stoppa, A.-M., Fuzibet, J.-G., Grosbois, B., Doyen, C., Ketterer, N., Sebban, C., Kolb, B., Chaleteix, C., Dib, M., Voillat, L., Fontan, J., Garderet, L., Jaubert, J., et al. (2011). Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood, 117(11), 3041-3044. https://doi.org/10.1182/blood-2010-08-300863 (Original work published 2011)